Head-To-Head Survey: Repligen (NASDAQ:RGEN) versus Cyclo Therapeutics (NASDAQ:CYTH)

Cyclo Therapeutics (NASDAQ:CYTH) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Profitability

This table compares Cyclo Therapeutics and Repligen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclo Therapeutics	-2,847.19%	N/A	-307.16%
Repligen	-4.64%	4.21%	2.94%

Volatility and Risk

Cyclo Therapeutics has a beta of -0.57, suggesting that its share price is 157% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.

Valuation and Earnings

This table compares Cyclo Therapeutics and Repligen”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclo Therapeutics	$870,725.00	24.54	-$20.06 million	($0.90)	-0.72
Repligen	$634.44 million	12.58	$35.60 million	($0.51)	-279.22

Repligen has higher revenue and earnings than Cyclo Therapeutics. Repligen is trading at a lower price-to-earnings ratio than Cyclo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

68.6% of Cyclo Therapeutics shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 29.8% of Cyclo Therapeutics shares are held by company insiders. Comparatively, 1.2% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Cyclo Therapeutics and Repligen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclo Therapeutics	0	2	1	0	2.33
Repligen	0	6	8	0	2.57

Cyclo Therapeutics currently has a consensus target price of $0.95, indicating a potential upside of 46.38%. Repligen has a consensus target price of $178.64, indicating a potential upside of 25.45%. Given Cyclo Therapeutics’ higher probable upside, analysts clearly believe Cyclo Therapeutics is more favorable than Repligen.

Summary

Repligen beats Cyclo Therapeutics on 10 of the 14 factors compared between the two stocks.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.